Prescient Therapeutics to present clinical data at prestigious US conference
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is...
Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Victoria has a mature, internationally recognised and thriving ecosystem that supports research and translation of...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.